Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

163.63 +0.61 (+0.37%)
Official Closing Price Updated: 7:00 PM EDT, Mar 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 17,047,695
Open 163.00
Bid (Size) 163.30 (5)
Ask (Size) 163.65 (1)
Prev. Close 163.02
Today's Range 162.48 - 164.13
52wk Range 140.68 - 169.99
Shares Outstanding 2,628,679,824
Dividend Yield 3.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+13.6%
+13.6%
1 Month
+2.5%
+2.5%
3 Month
+12.6%
+12.6%
6 Month
+0.3%
+0.3%
1 Year
+5.4%
+5.4%

More News

Read More
Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery
Via Benzinga
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
From Johnson & Johnson
Via Business Wire
Two Sectors Just Tried And Failed - And That’s Great For Us
Via Talk Markets
Topics Stocks / Equities
Historic Dividend Outperformance
Via Talk Markets
Topics ETFs Stocks / Equities
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
Via Benzinga
Honeywell Isn't Going to Let a Little Breakup Ruin Its Growth Plans
Via The Motley Fool
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
Via Benzinga
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Via Benzinga
Exposures Product Safety
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
Via Benzinga
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.
Via The Motley Fool
Resilient Investing: 3 Stocks Built to Weather Market Volatility
Via MarketBeat
Topics Economy
Exposures COVID-19 Economy
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now
Via The Motley Fool
Topics Stocks
Exposures US Equities
Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Via Benzinga
Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Kroger CEO Shake-Up
Via The Motley Fool
Cool, Calm, and Collected: 2 Dividend ETFs to Buy During the S&P 500 Sell-Off
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Generate Passive Income From This Low-Cost Vanguard ETF That Is Crushing the S&P 500 in 2025
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vanguard High Dividend Yield ETF vs Vanguard Dividend Appreciation ETF: Which Is Best for You?
Via The Motley Fool
Topics ETFs
Are High-Yield Dividend Stocks Best For Income-Focused Investors?
Via Talk Markets
Topics Stocks / Equities
How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket
Via Benzinga
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
Via The Motley Fool

Frequently Asked Questions

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded.
What exchange does Johnson & Johnson trade on?
Johnson & Johnson trades on the New York Stock Exchange
What is the ticker symbol for Johnson & Johnson?
The ticker symbol for Johnson & Johnson is JNJ on the New York Stock Exchange
What is the current price of Johnson & Johnson?
The current price of Johnson & Johnson is 163.63
When was Johnson & Johnson last traded?
The last trade of Johnson & Johnson was at 03/21/25 07:00 PM ET
What is the market capitalization of Johnson & Johnson?
The market capitalization of Johnson & Johnson is 430.13B
How many shares of Johnson & Johnson are outstanding?
Johnson & Johnson has 430B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.